[Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].
Identifieur interne : 000045 ( Main/Exploration ); précédent : 000044; suivant : 000046[Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].
Auteurs : A. Pérez-Rubio ; J M Eiros [Espagne]Source :
- Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [ 1988-9518 ] ; 2018.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (MeSH), Analyse coût-bénéfice (MeSH), Espagne (épidémiologie), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (économie), Humains (MeSH), Mâle (MeSH), Polysorbates (usage thérapeutique), Polysorbates (économie), Squalène (usage thérapeutique), Squalène (économie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccination (économie), Vaccins antigrippaux (usage thérapeutique), Vaccins antigrippaux (économie), État de santé (MeSH).
- MESH :
- prévention et contrôle : Grippe humaine.
- usage thérapeutique : Polysorbates, Squalène, Vaccins antigrippaux.
- économie : Grippe humaine, Polysorbates, Squalène, Vaccination, Vaccins antigrippaux.
- épidémiologie : Espagne.
- Adjuvants immunologiques, Analyse coût-bénéfice, Femelle, Humains, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, État de santé.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Cost-Benefit Analysis (MeSH), Female (MeSH), Health Status (MeSH), Humans (MeSH), Influenza Vaccines (economics), Influenza Vaccines (therapeutic use), Influenza, Human (economics), Influenza, Human (prevention & control), Male (MeSH), Polysorbates (economics), Polysorbates (therapeutic use), Spain (epidemiology), Squalene (economics), Squalene (therapeutic use), Vaccination (economics).
- MESH :
- chemical , economics : Influenza Vaccines, Polysorbates, Squalene.
- chemical , therapeutic use : Influenza Vaccines, Polysorbates, Squalene.
- chemical : Adjuvants, Immunologic.
- economics : Influenza, Human, Vaccination.
- epidemiology : Spain.
- prevention & control : Influenza, Human.
- Aged, Aged, 80 and over, Cost-Benefit Analysis, Female, Health Status, Humans, Male.
Abstract
OBJECTIVE
Influenza is an important health problem due to the mortality it can cause directly or indirectly as well as the complications and the economic and social costs it produces. Influenza epidemics are being addressed through vaccination campaigns aimed at preventing cases and complications, and the vaccine is officially recommended, as in the case of Spain, for certain risk groups, such as older people, chronic diseases and institutionalized population. The adjuvanted influenza vaccine with MF59, indicated for population over 65 years, has been shown to be more immunogenic than conventional influenza vaccines. The objective of this study is to assess the impact on the national and regional budget of the seasonal vaccination campaigns carried out in Spain using the MF59 adjuvanted vaccine compared to a conventional vaccine in a population older than 65 years.
METHODS
We analyzed the budgetary impact of the use of the MF59-adjuvanted vaccine in the national territory and by Autonomous Communities through a modeling of two alternatives, conventional vaccination versus adjuvant vaccination with MF59 in a population older than 65 years. The cases of avoided influenza, avoided complications and avoided costs, as well as the economic impact of the vaccination program have been calculated.
RESULTS
With the available information, the budgetary impact of using the influenza vaccine with MF59 in all the over 65 years, amounts to 6,967,288.10 €, avoiding for the national set a cost of 89.5 million Euros, which represents a potential savings of 82 million Euros and a cost-benefit ratio of 12.83.
CONCLUSIONS
The use of the influenza vaccine with the MF59 adjuvant to all those over 65 years would mean an increase in the efficiency of the vaccination programs currently proposed in all the Autonomous Communities and in the Spanish state.
PubMed: 29355006
PubMed Central: PMC6159358
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].</title><author><name sortKey="Perez Rubio, A" sort="Perez Rubio, A" uniqKey="Perez Rubio A" first="A" last="Pérez-Rubio">A. Pérez-Rubio</name></author><author><name sortKey="Eiros, J M" sort="Eiros, J M" uniqKey="Eiros J" first="J M" last="Eiros">J M Eiros</name><affiliation wicri:level="1"><nlm:affiliation>José María Eiros Bouza. Área de Microbiología. Sexta planta. Facultad de Medicina. Avda Ramón y Cajal 7. 47005. Valladolid, Spain. eiros@med.uva.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>José María Eiros Bouza. Área de Microbiología. Sexta planta. Facultad de Medicina. Avda Ramón y Cajal 7. 47005. Valladolid</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29355006</idno><idno type="pmid">29355006</idno><idno type="pmc">PMC6159358</idno><idno type="wicri:Area/Main/Corpus">00074</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00074</idno><idno type="wicri:Area/Main/Curation">000074</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000074</idno><idno type="wicri:Area/Main/Exploration">000074</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].</title><author><name sortKey="Perez Rubio, A" sort="Perez Rubio, A" uniqKey="Perez Rubio A" first="A" last="Pérez-Rubio">A. Pérez-Rubio</name></author><author><name sortKey="Eiros, J M" sort="Eiros, J M" uniqKey="Eiros J" first="J M" last="Eiros">J M Eiros</name><affiliation wicri:level="1"><nlm:affiliation>José María Eiros Bouza. Área de Microbiología. Sexta planta. Facultad de Medicina. Avda Ramón y Cajal 7. 47005. Valladolid, Spain. eiros@med.uva.es.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>José María Eiros Bouza. Área de Microbiología. Sexta planta. Facultad de Medicina. Avda Ramón y Cajal 7. 47005. Valladolid</wicri:regionArea></affiliation></author></analytic><series><title level="j">Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</title><idno type="eISSN">1988-9518</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Cost-Benefit Analysis (MeSH)</term><term>Female (MeSH)</term><term>Health Status (MeSH)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (economics)</term><term>Influenza Vaccines (therapeutic use)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Polysorbates (economics)</term><term>Polysorbates (therapeutic use)</term><term>Spain (epidemiology)</term><term>Squalene (economics)</term><term>Squalene (therapeutic use)</term><term>Vaccination (economics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (MeSH)</term><term>Analyse coût-bénéfice (MeSH)</term><term>Espagne (épidémiologie)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (économie)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Polysorbates (usage thérapeutique)</term><term>Polysorbates (économie)</term><term>Squalène (usage thérapeutique)</term><term>Squalène (économie)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Vaccination (économie)</term><term>Vaccins antigrippaux (usage thérapeutique)</term><term>Vaccins antigrippaux (économie)</term><term>État de santé (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Influenza Vaccines</term><term>Polysorbates</term><term>Squalene</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term><term>Polysorbates</term><term>Squalene</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Influenza, Human</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Polysorbates</term><term>Squalène</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term><term>Polysorbates</term><term>Squalène</term><term>Vaccination</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Espagne</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cost-Benefit Analysis</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Analyse coût-bénéfice</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>État de santé</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>Influenza is an important health problem due to the mortality it can cause directly or indirectly as well as the complications and the economic and social costs it produces. Influenza epidemics are being addressed through vaccination campaigns aimed at preventing cases and complications, and the vaccine is officially recommended, as in the case of Spain, for certain risk groups, such as older people, chronic diseases and institutionalized population. The adjuvanted influenza vaccine with MF59, indicated for population over 65 years, has been shown to be more immunogenic than conventional influenza vaccines. The objective of this study is to assess the impact on the national and regional budget of the seasonal vaccination campaigns carried out in Spain using the MF59 adjuvanted vaccine compared to a conventional vaccine in a population older than 65 years.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We analyzed the budgetary impact of the use of the MF59-adjuvanted vaccine in the national territory and by Autonomous Communities through a modeling of two alternatives, conventional vaccination versus adjuvant vaccination with MF59 in a population older than 65 years. The cases of avoided influenza, avoided complications and avoided costs, as well as the economic impact of the vaccination program have been calculated.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>With the available information, the budgetary impact of using the influenza vaccine with MF59 in all the over 65 years, amounts to 6,967,288.10 €, avoiding for the national set a cost of 89.5 million Euros, which represents a potential savings of 82 million Euros and a cost-benefit ratio of 12.83.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>The use of the influenza vaccine with the MF59 adjuvant to all those over 65 years would mean an increase in the efficiency of the vaccination programs currently proposed in all the Autonomous Communities and in the Spanish state.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29355006</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1988-9518</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</Title><ISOAbbreviation>Rev Esp Quimioter</ISOAbbreviation></Journal><ArticleTitle>[Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].</ArticleTitle><Pagination><MedlinePgn>43-52</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">perez18jan2018</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Influenza is an important health problem due to the mortality it can cause directly or indirectly as well as the complications and the economic and social costs it produces. Influenza epidemics are being addressed through vaccination campaigns aimed at preventing cases and complications, and the vaccine is officially recommended, as in the case of Spain, for certain risk groups, such as older people, chronic diseases and institutionalized population. The adjuvanted influenza vaccine with MF59, indicated for population over 65 years, has been shown to be more immunogenic than conventional influenza vaccines. The objective of this study is to assess the impact on the national and regional budget of the seasonal vaccination campaigns carried out in Spain using the MF59 adjuvanted vaccine compared to a conventional vaccine in a population older than 65 years.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed the budgetary impact of the use of the MF59-adjuvanted vaccine in the national territory and by Autonomous Communities through a modeling of two alternatives, conventional vaccination versus adjuvant vaccination with MF59 in a population older than 65 years. The cases of avoided influenza, avoided complications and avoided costs, as well as the economic impact of the vaccination program have been calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">With the available information, the budgetary impact of using the influenza vaccine with MF59 in all the over 65 years, amounts to 6,967,288.10 €, avoiding for the national set a cost of 89.5 million Euros, which represents a potential savings of 82 million Euros and a cost-benefit ratio of 12.83.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of the influenza vaccine with the MF59 adjuvant to all those over 65 years would mean an increase in the efficiency of the vaccination programs currently proposed in all the Autonomous Communities and in the Spanish state.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pérez-Rubio</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Eiros</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>José María Eiros Bouza. Área de Microbiología. Sexta planta. Facultad de Medicina. Avda Ramón y Cajal 7. 47005. Valladolid, Spain. eiros@med.uva.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Impacto económico y sanitario de la utilización de vacuna antigripal adyuvada con MF59 en población mayor de 65 años en España.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Quimioter</MedlineTA><NlmUniqueID>9108821</NlmUniqueID><ISSNLinking>0214-3429</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29355006</ArticleId><ArticleId IdType="pii">perez18jan2018</ArticleId><ArticleId IdType="pmc">PMC6159358</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Prev Med Hyg. 2011 Mar;52(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21710816</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2012 Feb;8(2):216-27</Citation><ArticleIdList><ArticleId IdType="pubmed">22426371</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Dec 9;31(51):6122-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23933368</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2001 Mar 21;19(17-19):2673-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11257408</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2012 Sep 15;176(6):527-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22940713</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2013 Oct 1;178(7):1139-45</Citation><ArticleIdList><ArticleId IdType="pubmed">23863759</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Biol Ther. 2010 Apr;10(4):639-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20218923</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Oct 16;25(42):7313-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17889411</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1994 Dec 7;272(21):1661-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7966893</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Jul 8;23 Suppl 1:S10-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15908062</ArticleId></ArticleIdList></Reference><Reference><Citation>Aten Primaria. 2006 Sep 30;38(5):260-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17020710</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Feb 20;24(8):1159-69</Citation><ArticleIdList><ArticleId IdType="pubmed">16213065</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2013 Sep;85(9):1591-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23852684</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerontology. 2003 May-Jun;49(3):177-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12679609</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876</Citation><ArticleIdList><ArticleId IdType="pubmed">20166072</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2007 Sep-Oct;10(5):336-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17888098</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2004 Sep 18;329(7467):660</Citation><ArticleIdList><ArticleId IdType="pubmed">15313884</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2017 Aug 24;22(34):</Citation><ArticleIdList><ArticleId IdType="pubmed">28857047</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><noCountry><name sortKey="Perez Rubio, A" sort="Perez Rubio, A" uniqKey="Perez Rubio A" first="A" last="Pérez-Rubio">A. Pérez-Rubio</name></noCountry><country name="Espagne"><noRegion><name sortKey="Eiros, J M" sort="Eiros, J M" uniqKey="Eiros J" first="J M" last="Eiros">J M Eiros</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000045 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000045 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29355006
|texte= [Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29355006" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |